COVA
- Interim analysis for Part 2 (155 patients) in Q3 2021
- Early Access Program (EAP) authorization in Brazil in February 2022
- Early termination of patient enrolment in April 2022
- Phase 2/3 study results expected in Q3 2022
- Application for conditional approval in Europe and the EUA in the US in 2023